Medications belonging to the GLP-1 (glucagon-like peptide-1) receptor agonist class, widely known for their effectiveness in treating type 2 diabetes and obesity, may also prove beneficial for certain chronic skin disorders. This conclusion comes from a review of current evidence published in the journal Pharmaceutics.
The drugs in question include GLP-1 receptor agonists such as Semaglutide and Liraglutide. Originally developed to improve blood sugar control and promote weight loss, these medications are increasingly attracting attention for their anti-inflammatory properties.
Dermatologists first became interested in these drugs after observing patients with diabetes and obesity. Physicians noticed that some individuals experienced not only metabolic improvements but also reductions in the severity of skin diseases, particularly Psoriasis.
Subsequent research revealed that GLP-1 receptors are present not only in the pancreas and gastrointestinal tract but also on immune cells. This discovery suggested that these medications might directly influence the chronic inflammation underlying many skin disorders.
Researchers have focused especially on psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa. Although these conditions differ in their symptoms, they share a common feature: persistent overactivation of the immune system. Studies indicate that GLP-1 receptor agonists may affect macrophages, neutrophils, and T cells while reducing the production of pro-inflammatory molecules such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17).
At present, the strongest evidence has been gathered for psoriasis. Several studies have reported improvements in skin symptoms among patients treated with semaglutide or liraglutide. However, researchers emphasize that it remains difficult to determine how much of the benefit stems from the drugs’ direct anti-inflammatory effects and how much results from weight loss and improved metabolic health.
Another promising area is the treatment of atopic dermatitis. Experimental studies suggest that GLP-1 receptor agonists may influence inflammatory pathways and support tissue repair. However, clinical evidence remains limited, and further research is needed before firm conclusions can be drawn.
Beyond their anti-inflammatory effects, researchers have identified another potential advantage. Emerging evidence suggests that GLP-1 medications may improve tissue blood flow and accelerate wound healing. This could be particularly important for people with diabetes, for whom chronic ulcers and slow-healing wounds remain major medical challenges.
The authors of the review stress that it is far too early to consider these drugs a replacement for established treatments for psoriasis or atopic dermatitis. At present, they are viewed primarily as a complementary therapy, especially for patients whose skin conditions coexist with obesity or diabetes.
Nevertheless, the findings are encouraging. If future clinical studies confirm these observations, medications originally designed to treat metabolic disorders could become one of the most compelling examples of the growing intersection between dermatology, immunology, and diabetes care in the management of chronic diseases.
Follow NEWS.am Medicine on Facebook and Twitter